In mice, Lkb1 deletion and activation of Kras G12D results in lung tumors with a high penetrance of lymph node and distant metastases. We analyzed these primary and metastatic de novo lung cancers with integrated genomic and proteomic profiles, and have identified gene and phosphoprotein signatures associated with Lkb1 loss and progression to invasive and metastatic lung tumors. These studies revealed that SRC is activated in Lkb1-deficient primary and metastatic lung tumors, and that the combined inhibition of SRC, PI3K, and MEK1/2 resulted in synergistic tumor regression. These studies demonstrate that integrated genomic and proteomic analyses can be used to identify signaling pathways that may be targeted for treatment.
INTRODUCTION
Lung cancer is the leading cause of cancer mortality worldwide. Genetic analyses and gene expression profiling of primary human lung tumors have identified several aberrant signaling pathways involved in the initiation of non-small cell lung cancer (NSCLC) (Bild et al., 2006) . Although many of these pathways are also likely to be involved in NSCLC progression and metastases, it is clear that the metastatic phenotype requires additional pathway perturbations that regulate cell motility, cell adhesion, the epithelial to mesenchymal transition (EMT), and extracellular matrix remodeling (Nguyen and Massague, 2007) . Because the development of metastases causes much of the morbidity and incurability of epithelial cancers, there is
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an urgent need to elucidate the events underlying this biological process.
The paucity of matched primary and metastatic human lung tumors has made it difficult to examine the genetic changes involved in the progression and metastasis of NSCLC. Studies using genetically engineered mice have demonstrated that the activation of certain combinations of oncogenes is sufficient for lung tumor initiation (Engelman et al., 2008; Jackson et al., 2001; Ji et al., 2006a Ji et al., , 2006b ) and that additional genetic events are required for tumor progression (Iwanaga et al., 2008; Jackson et al., 2005) or metastases (Ji et al., 2007; Kim et al., 2009) . We recently showed that the loss of the Lkb1 tumor suppressor gene in Kras-driven lung tumors results in metastases to lymph node and distant sites in mice (Ji et al., 2007) . Moreover, we and others have shown that LKB1 is inactivated by point mutations or deletions in at least 15%-35% of NSCLC and concurrent KRAS and LKB1 mutation is observed in 4%-10% of NSCLC (Carretero et al., 2004; Koivunen et al., 2008; Ji et al., 2007; Matsumoto et al., 2007; Sanchez-Cespedes et al., 2002) .
In humans, germline mutation of LKB1 results in the PeutzJeghers syndrome, a familial cancer syndrome characterized by intestinal hamartomas and an increased risk for epithelial cancers, including lung cancers (Hearle et al., 2006) . The LKB1 gene encodes a serine/threonine kinase that phosphorylates several substrates, many of which are also kinases (Alessi et al., 2006) . However, identification of the pathways responsible for the prometastatic effects of Lkb1 loss has yet to be made.
To identify altered signal transduction pathways involved in the progression and metastases of Lkb1-deficient lung tumors, we have performed an unbiased, integrated analysis of genomic and phosphoproteomic signatures of primary and metastatic mouse lung tumors.
RESULTS

Lkb1-Deficient Metastatic Lung Tumors Harbor Unique Gene Expression Changes
Lung-specific activation of mutant Kras G12D results in bronchoalveolar hyperplasia and low grade adenocarcinomas (Jackson et al., 2001) . We recently observed that concomitant loss of the Lkb1 tumor suppressor gene leads to a broadened histologic spectrum of lung tumors that have a high propensity for local invasion and metastases (Ji et al., 2007 Figure S1A available online).
To better characterize the molecular alterations associated with Lkb1 loss and metastasis, we derived expression signatures from our mouse lung tumors that reflected the gene expression changes induced by Lkb1 loss in primary tumors (Lkb1) by comparing primary Kras tumors with primary Kras/Lkb1 tumors and changes associated with metastases (Mets) by comparing Kras/Lkb1 primary tumors to Kras/Lkb1 metastases. We used a two-class unpaired differential expression analysis and a false-discovery rate (FDR) of < 0.01. The resulting ''Lkb1'' and ''Mets'' gene signatures contain 727 and 757 differentially expressed genes, respectively ( Figure 1A ). In aggregate, these results indicate that Lkb1 loss induces significant transcriptional changes in primary cancers and that there are further gene expression alterations that characterize the progression to lymph node and distant metastasis.
A Cross-Species Comparison across Mouse and Human Data Sets Validates an Expression Signature of Metastases as Prognostic in Human NSCLC
We next sought to determine whether this Mets signature predicted clinical outcome in human lung cancer patients. Using the human orthologs of the murine genes in the Mets signature, we interrogated two publicly available gene expression data sets of primary NSCLCs, annotated for either overall survival and histologic grade (Director's Challenge Consortium data set, Shedden et al., 2008) or metastasis-free recurrence (MSKCC data set 2, Nguyen et al., 2009) . The gene expression profiles of these human NSCLCs were queried for the presence or absence of our Mets expression signature as defined by coordinate upregulation and downregulation of overexpressed or underexpressed genes from the Mets signature.
Consistent with the notion that our Mets gene signature correlates with a proclivity toward metastasis, patients with tumors expressing the Mets signature had a significantly worse survival and increased occurrence of metastasis than did patients with tumors without Mets signature expression in these two data sets ( Figure 1B ). In contrast, the Lkb1 signature, generated by comparing Kras tumors to Kras/Lkb1 primary tumors, had no prognostic value (data not shown). These data suggest that the same gene expression changes induced Table S1 and Figure S1 .
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Targets for LKB1-Deficient Lung Cancers during progression of Lkb1 deficient tumors to metastases in this murine model faithfully recapitulate those associated with the development of advanced incurable disease in human primary NSCLC and might be useful to prognosticate patients with early stage lung cancer. The disparity in the ability of the Lkb1 signature and the Mets signature in predicting survival suggest that either there is a subset of cells in the primary tumor that is destined for metastases that cannot be discerned from expression analyses of the whole tumor or that additional expression changes developed at the site of metastases from cancer-stromal cell interactions. Lastly, and as shown on Figure S1B , the repressed component of the Mets signature showed a strong and significant correlation with the human samples that are mutant for both KRAS and LKB1 in the University of North Carolina data set (Ji et al., 2007) .
Lkb1-Deficient Metastases have Upregulation of EMT-Associated Gene Signatures
Activation of oncogenic signaling pathways has been shown to induce broad gene expression changes that can be used to generate gene expression or metagene signatures (Nevins and Potti, 2007) . In order to better understand the biological basis for tumor metastasis in this model, we compared genes that were upregulated in the metastatic progression of these mouse lung tumors to known lists of transcripts associated with specific alteration in known pathways. Using gene set enrichment analyses, we identified gene signatures that were significantly enriched in our Kras/Lkb1 metastases relative to our primary Kras and Kras/Lkb1 lung tumors (Segal et al., 2004) . Specifically, a collection of curated gene sets (Table  S1 ) provided by the Molecular Signatures Database (MsigDB, broad.mit.edu/gsea/msigdb) and those collected from the literature (Ben-Porath et al., 2008; Bild et al., 2006; Cole et al., 2008; Onder et al., 2008) were used to interrogate our gene expression data set with the Genomica analysis tool (genomica.weizmann.ac.il).
A total of 32 of the 51 curated, cancer-related, gene sets appeared to be significantly enriched and highly expressed (p < 0.05, FDR < 0.05) in our data set of Kras/Lkb1 metastases relative to Kras and Kras/Lkb1 primary lung tumors ( Figure 1C ). This included a number of gene signatures implicated in the metastatic process such as focal adhesion alterations, EMT, increased TGF-b and b-catenin signaling, as well as embryonic stem (ES) cell expression signature and transcription factors implicated in ES cell phenotype such as TCF3 and OCT4 (BenPorath et al., 2008; Bild et al., 2006; Cole et al., 2008; Onder et al., 2008) . A number of these findings were validated. For example, the canonical EMT markers (Kalluri and Weinberg, 2009 ), Vimentin, Snail, Twist1, N-cadherin, Acta2, and fibronectin seen in this signature were validated by real-time polymerase chain reaction (RT-PCR) ( Figure S1C ). Multiplex bead assay confirmed the elevated TGF-b levels in lysates from Kras/Lkb1 metastases ( Figure S1D ). Furthermore, immunostaining demonstrated the presence of canonical EMT markers such as vimentin and fibronectin in both Kras/Lkb1 primary and metastatic tumors ( Figure S1E ). Although components of these oncogenic signatures were observed in Lkb1-deficient primary tumors, their levels appeared to be higher in Lkb1-deficient metastases ( Figure 1C and Figures S1C-S1E). These results suggest that additional molecular events cooperate with Lkb1 loss to maximally activate these pathways during metastatic progression.
Phosphoscan of LKB1-Deficient Cells Identifies Activation of SRC Family Kinases
To complement our transcriptional analysis, we assessed how loss of Lkb1 impacted tyrosine kinase signaling cascades. We hypothesized that if Lkb1 loss resulted in significant activation of specific tyrosine kinases, then we should detect increased phosphorylation of their respective substrates. To complement the analysis of murine tumors, we generated paired LKB1 and control knockdown cells in the BEAS-2B human bronchial epithelial cell line (Reddel et al., 1988) , which is immortalized with SV40 Large T antigen, (BEAS-2B-LKB1D and BEAS-2B-NT, respectively) and in the KRAS mutant, LKB1 wild-type NSCLC cell line H358 (H358-LKB1D and H358NT), which has been previously shown not to express markers of EMT (Figure 2A ). These paired human cell lines, along with our mouse lung primary and metastatic tumors, were used for generating phosphotyrosine signatures with previously described methods (Rikova et al., 2007) . Specifically, whole cell extracts from cell lines or pooled tissue lysates (two pools with three tumor samples each from Kras, Kras/Lkb1 primary tumors, and Kras/Lkb1 metastases) were immunoprecipitated with a phosphotyrosine specific antibody, and the immunoprecipitates were subjected to mass spectrometry (MS) analysis to identify and quantify phosphopeptides.
We identified 441, 259, and 363 phosphotyrosine sites in BEAS-2B, H358 and mouse lung tumors, respectively, that were enriched in the absence of LKB1 (Figure 2A ). Forty-one of these LKB1-affected tyrosine phosphorylated peptides were noted to overlap across all three data sets ( Figure 2A , cluster A), whereas an additional 26 peptides and 10 peptides were noted to overlap between the BEAS-2B / mouse tumor and H358 / mouse tumor data sets, respectively ( Figure 2A , clusters B and C). An examination of the putative upstream kinases Table of coordinately regulated, LKB1-dependent phosphotyrosine sites. Details of the LKB1-dependent phosphotyrosine sites found to be coordinately regulated across data sets are listed and include the phosphorylated protein, the tyrosine site, heatmaps of log2 ratios of indicated comparisons (red, positive log2 ratios; blue, negative log2 ratios), as well as the putative upstream kinase. The GEP (gene expression profiling) data column indicates the level of expression of the genes encoding these proteins between Kras/Lkb1 (primary or mets) versus Kras murine tumors comparisons (red dots = significantly overexpressed, green dots = significantly underexpressed, and orange dots = no significant change). Subscript 1 indicates upstream kinases obtained from PhosphoELM, HPRD and Swissprot databases. Superscript 2 indicates upstream kinases obtained from NetworKIN database (see also Figure S2 ).
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Targets for LKB1-Deficient Lung Cancers known to phosphorylate these tyrosine residues suggested that a number of kinases were activated in association with LKB1 deficiency. These analyses pointed to a particularly central role for SRC activation that was not only highly phosphorylated, but that is also predicted to be an upstream kinase for 13 sites of 40 differentially phosphorylated proteins among our data sets ( Figure 2B ). Moreover, Kras/Lkb1 primary tumors and metastases showed a significant hyperphosphorylation of a Src substrates signature, as assessed by Gene Set Enrichment Analysis (GSEA) ( Figure S2A ).
The Nonreceptor Tyrosine Kinases, SRC and Focal Adhesion Kinase, Are Activated by LKB1 Loss We speculated that integration of the gene expression and phosphoproteomics data sets would be a powerful approach to identify functionally significant molecular alterations in Lkb1-deficient lung cancers. We noted that gene signatures of focal adhesion activation were highly enriched in metastases from Kras/Lkb1 lung tumors ( Figure 1C ). Focal adhesions are dynamic subcellular structures known to mediate cell attachment to the extracellular matrix and are composed of over 50 proteins including focal adhesion kinase (FAK or PTK2), Paxillin, and SRC (Burridge et al., 1997; Playford and Schaller, 2004; Yeatman, 2004 ). As noted above, SRC activation was the most prominent signature emerging from our phosphoproteomic analysis and there was also strong evidence for FAK activation. To better integrate our data examining the impact of LKB1 loss on the focal adhesion pathway, components of the pathway upregulated at the gene expression or tyrosine phosphorylation level were colored yellow and red, respectively, and visualized on a KEGG pathway map (Figure 3) . The results appear to show convergence on the activation of SRC, FAK, and their downstream pathways by Lkb1 loss and implicate alterations in the expression and activity of focal adhesion regulators in the pathogenesis of Lkb1-deficient lung cancers.
SRC and FAK activation results in focal adhesion disassembly and turnover, through downregulation of RhoA, resulting in increased cellular motility (Arthur et al., 2000; Yeatman, 2004) . Given the key role of cellular motility and migration in the process of metastasis, we next determined whether LKB1 regulates these key components of focal adhesion dynamics. To this end, whole cell extracts of the H358 cells expressing control shRNA (NT) or four different shRNA sequences targeting LKB1 (A, B, C, and D) were immunoblotted using antibodies against the activating tyrosine phosphorylation sites in SRC, and FAK (Y416 and Y576/577, respectively). As shown in Figure 4A cells showed an increase of AMPK (T172) and decrease of ACC (S79) phosphorylation, as well as an increase of S6 (S240/S244) phosphorylation ( Figure S3A ).
Because Phosphoscan and western blot analyses detect a phosphorylation site (Y416) that is common to all SRC family kinases (SFKs) including SRC, FYN, LYN, LCK, HCK FGR, and YES, we interrogated the phosphorylation status of SFKs affected by LKB1 loss in NCI-H358 and A549 cell lines using a Luminex bead assay. As shown in Figures S3B and S3C , H358 cells preferentially activate SRC and LYN, whereas A549 activates only SRC. In both cases, LKB1 loss promoted activation of SFKs. In addition, analyses of the protein lysates from H358-LKB1D and H358-NT cells with a protein array with sitespecific phosphoantibodies further validated SRC, FAK, and other targets obtained by MS analyses of Kras/Lkb1 murine model ( Figure S3D ). These changes in SRC and FAK suggest impaired adhesion and increased cellular motility (Yeatman, 2004) . To assess whether loss of LKB1 affects the motility of these NSCLC cells, we performed a scratch assay. H358 cells with LKB1 knockdown (LKB1D) migrated more rapidly into the scratched space than the control cells (NT), whereas proliferation and viability of the two cells lines were identical in vitro ( Figure 4B and Figure S3E ). LKB1 loss also increased in vitro invasion of H358 cells, as assessed by Boyden chamber assay ( Figure 4C ). Therefore, loss of LKB1 appears to increase the kinase activity of several key proteins involved in focal adhesion dynamics and promote cell motility and invasion.
We also determined the consequences of LKB1 loss in NSCLC cells in vivo. To this end, we grew H358-LKB1D and H358-NT cells as subcutaneous xenograft tumors in nude mice and measured mean tumor volume 2 weeks after implantation. Tumors derived from H358 LKB1-deficient cells were significantly larger than those expressing a nonspecific shRNA, suggesting that loss of LKB1 promotes primary tumor growth in addition to metastasis ( Figure 4D ). Immunohistochemical (IHC) staining with antibodies that specifically recognize human (but not mouse) antigens showed increased levels of vimentin in the H358-LKB1D xenografts than in the H358-NT tumors ( Figure 4E ), in agreement with the previous results suggesting that loss of LKB1 promotes EMT ( Figure 4A and Figure S1E ). Elevated vimentin staining was particularly prominent at the edge of tumors suggesting that the EMT in the LKB1-deficient tumor cells may have also involved signals from the adjacent stromal cells ( Figure 4E ). In agreement to these observations, H358 cells without LKB1 (LKB1D) released significantly more TGF-b1/2 than H358 control (NT) cells and nuclear b-catenin accumulation was more prevalent in LKB1D than in NT cells ( Figures S3F and  S3G ). These observations support the notion that LKB1 loss plays an important role in EMT. 
LKB1 Loss Heightens Dependence on SRC and FAK Signaling for Cell Adhesion and Migration
Our integrated gene expression and Phosphoscan results suggest that LKB1 loss might promote metastasis through activation of SRC and FAK signaling. Metastasis is a multistep process involving cell interactions with extracellular matrix (ECM) components, increased cell migration and tumor invasion (Mitra and Schlaepfer, 2006) . These individual processes can both modulate and be modulated by SRC and FAK activity (Huveneers and Danen, 2009; Shibue and Weinberg, 2009 ). We hypothesized that SRC/FAK activation induced by LKB1 loss resulted in an increased dependence upon these signaling pathways for cell adhesion to ECM. To test this hypothesis, we plated 5 3 10 5 cells with or without LKB1 knockdown on tissue culture wells coated with collagen I, collagen IV, fibronectin, laminin I, fibrinogen, or BSA in the presence of the SRC-family kinase inhibitor Dasatinib or the FAK inhibitor PF573228 (Johnson et al., 2005; Slack-Davis et al., 2007) . Among the ECM components tested, only collagen I or IV could promote the adherence of H358 cells ( Figure 5A and data not shown). Knockdown of LKB1 in H358 cells did not have
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Targets for LKB1-Deficient Lung Cancers an appreciable effect on the baseline adhesion of H358 cells to either collagen I or IV. However, treatment of H358 cells with Dasatinib or PF573228 resulted in a dose-dependent decrease in cell adhesion that was more prominent in H358 cells with LKB1 knockdown ( Figure 5B ). Similar results were obtained when H358 cells with or without LKB1 expression were examined for the effects of Dasatinib and PF573228 on cell migration ( Figure 5C ). These observations support the notion that the activation of SRC and FAK due to LKB1 loss promotes dependence upon these signaling pathways for cell migration and adhesion to extracellular matrix components as well as migration.
Combined Inhibition of PI3K-mTOR, MEK, and SRC Family Kinases Results in Synergistic In Vivo Tumor Response in LKB1-Defective Lung Tumors
We had previously observed that dual inhibition of PI3K-mTOR and MEK with BEZ235 (a PI3K-mTOR inhibitor) and AZD2644 (a MEK1/2 inhibitor) resulted in an 80% reduction of tumor volume of Kras-dependent murine lung tumor model (Engelman , 2008) . Surprisingly, treatment of Kras/Lkb1 mice with the same combination showed that these lung tumors were largely unresponsive ( Figure 6A ). Figure 6A ) and histology ( Figure 6B ). These in vivo data suggest that Lkb1 loss results in reduced sensitivity to the combined inhibition of PI3K and MEK, at least in part, through activation of SRC. Moreover, although Dasatinib alone in Kras/ Lkb1 lung cancer model did not provide overall survival benefit over vehicle in this Kras/Lkb1 lung cancer model, it blocked metastasis (Table S2) .
Gene expression profiling of short term treated tumors showed that all treatments were able to revert Lkb1 and Mets signatures (Table S2) 
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DISCUSSION
Cancer genomic studies have established a number of oncogene and tumor suppressor pathways as important for the initiation and maintenance of neoplastic lesions in NSCLC. However, the molecular alterations necessary for invasion and metastasis of NSCLC are less well-defined. We have previously reported that deletion of the Lkb1 tumor suppressor gene in the context of Kras-driven murine lung tumors promotes invasion and metastasis (Ji et al., 2007) . Here we extend these findings to show that Kras/Lkb1 primary and metastatic tumors have upregulated expression of markers and inducers of EMT. Furthermore, through an integrated genomic and phosphoproteomic analysis of mouse lung primary and metastatic tumors, we have determined that two key modulators of focal adhesion dynamics, SRC and FAK, are upregulated by Lkb1 loss during NSCLC progression. Similarly, LKB1 loss in vitro also resulted in SRC activation, increased motility, and SRCdependent adhesion. In fact, migration was selectively abrogated by SRC and FAK inhibition in LKB1-deficient cells. Finally, whereas Kras mutant lung tumors are sensitive to the combined inhibition of the PI3K and MEK pathways, we have found that Kras/Lkb1 tumors are resistant to these inhibitors, and that sensitivity can be restored by additional targeting of SRC. It also important to note that addition of Dasatinib to combined PI3K/MEK inhibition induced tumor shrinkage in the LKB1-deficient tumors. This reveals an important role for SFKs in tumor growth and promoting resistance to combined PI3K/MEK inhibition. Indeed, in addition to their prominent roles in tumor migration and adhesion, SFKs are also essential for transducing signals from RTKs and integrins to promote cell survival and proliferation (Yeatman, 2004) . It was somewhat surprising that single-agent Dasatinib led to increased volume of Kras/Lkb1 tumors ( Figure 6 ) and persisting Akt and EMT signatures (Table S3 ). Although we cannot fully explain this observation, it is tempting to speculate that SRC inhibition led to loss of a feedback mechanism resulting in increased tumor growth or to a change in the interactions between tumor cells and stroma or immune cells resulting in tumor growth. Collectively, these results point toward a mechanism underlying the increased propensity for metastases seen in Lkb1-deficient lung tumors and identify SRC as a molecularly targetable pathway for the treatment of LKB1-deficient NSCLC in humans.
Tumor metastasis is a complex, multistage process that involves both initiating functions, such as invasion and angiogenesis, as well as metastasis progression functions such as extravasation and survival (Nguyen and Massague, 2007) . EMT has been implicated in metastasis initiation and involves loss of cell-cell junction proteins as well as a conversion of stationary cells to motile cells capable of invading through the ECM . Our gene expression analysis suggests that LKB1 loss results in the aberrant expression of a number of oncogenic pathways and transcription factors known to be inducers of EMT such as SNAI1, TWIST1, and the TGF-b and b-catenin pathways (Kalluri and Weinberg, 2009; Nguyen and Massague, 2007; Yang and Weinberg, 2008) . Although the mechanism by which LKB1 loss promotes EMT remains to be determined, we observe that NSCLC cells lacking LKB1 exhibit higher nuclear localization of b-catenin and increased release of TGF-b ( Figures S3F and S3G ) suggesting that LKB1 loss may have a direct cell autonomous role in promoting the EMT program. The expression signatures derived from Kras/Lkb1 metastasis enriched for EMT correlate with NSCLC patients with metastatic potential and worsened survival ( Figure 1B) , whereas expression signatures derived from Kras primary tumors or Kras/Lkb1 tumors did not correlate with survival thus have no prognostic value. Importantly, the presence of Mets signature in primary tumor samples, including a subset of double KRAS and LKB1 mutants, suggests that a subset of primary tumors harbor cells destined for metastasis.
Part of the roadblock in defining the pathways involved in invasion and metastases in human NSCLC has been the difficulty in obtaining tissue from metastatic sites. Through the use of a Krasdriven, Lkb1-deficient genetically engineered mouse model of lung cancer, we have been able to collect matched primary and metastatic tumors and apply integrated gene expression and phosphoproteomic analysis to define altered signal transduction pathways. The utilization of complex murine cancer models to identify signal transduction pathways altered in cancer progression and metastases might serve as a paradigm for other solid tumors that suffer from similar barriers to tissue acquisition.
Previous work from our lab has shown that dual inhibition of the PI3K and MEK pathways in Kras-driven murine NSCLC results in synergistic tumor responses (Engelman et al., 2008) . Strikingly, Lkb1 loss renders these tumors substantially more resistant to this therapeutic regimen; therefore, Lkb1 loss could serve as a negative predictor of the responses to the therapy. Despite the broad gene expression changes seen in the setting of Lkb1 loss and progression to metastases, it is notable that we were able to define a candidate mediator of Lkb1-deficient tumor growth, SRC, in which additional inhibition-with Dasatinib-was able to restore sensitivity to inhibition of PI3K and MEK in vivo. A limitation of this analysis is that Dasatinib is a potent inhibitor of other kinases, e.g., ABL, which was also activated to a lesser degree in Lkb1-deficient tumors. Future studies will determine the relative importance of SFKs versus other Dasatinib targets in mediating the response to this agent. Lastly, Kras/Lkb1 mice treated with Dasatinib alone did not show any evidence of metastasis (Table S2 ). This further reinforces our data that the Src family members are important mediators of metastatic progression in Kras/Lkb1-driven lung cancer. In conclusion, our results imply that despite the complex transcriptional and signaling changes that occur in the setting of LKB1 loss and progression of NSCLC, these tumors may still be addicted to isolated oncogenic events that can be successfully therapeutically targeted.
EXPERIMENTAL PROCEDURES
Mouse Colony and Tumor Collection All mice were housed and treated in accordance with protocols approved by the institutional care and use committees for animal research at the DanaFarber Cancer Institute. Kras and Kras/Lkb1 mice were treated with 5 3 10 6 p.f.u. adeno-Cre (University of Iowa viral vector core) intranasally as previously described (Ji et al., 2007) . Primary lung adenocarcinomas and metastases were macrodissected and formalin fixed or frozen in liquid nitrogen and stored at À80
C until use.
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Histology and Immunohistochemical Analysis Formalin-fixed tissues were paraffin embedded, sectioned at 5 mm, and hematoxylin and eosin (H&E) stained (Department of Pathology in Brigham and Women's Hospital). Unstained slides were deparaffinized in xylene and rehydrated sequentially in ethanol. Antigen retrieval was performed by boiling slides in 10 mM sodium citrate (pH 6.0) for 30 min. Primary antibodies were diluted in TBST with 5% goat serum and incubated overnight at 4 C (see Supplemental experimental procedures for detailed list of primary antibodies). Detection was performed using the avidin-biotin horseradish peroxidase technique in which 3,3 00 -diaminobenzidine was the chromogenic substrate.
Analysis of Microarray Gene Expression Data
Gene expression profiling methods (Total RNA isolation and microarray processing) are available in Supplemental Experimental Procedures. Clustering and differential expression analyses were performed using the Gepas Analysis suite (Tarraga et al., 2008) and GenePattern (Reich et al., 2006 ) with procedures described in Supplemental Experimental Procedures. Genomica software (http://genomica.weizmann.ac.il/) was used to identify enrichment patterns of a custom collection of experimental signatures associated with different phenotypes and cancer-related events (Ben-Porath et al., 2008; Segal et al., 2004 ) (see Table S1 for detailed description). In brief, the data were log2 transformed and mean centered. Genes whose expression was 2-fold or greater than the mean expression level were scored. Enrichment of overexpressed or underexpressed genes that belong to each tested gene signature was calculated using a hypergeometric test and an FDR calculation to account for multiple hypothesis testing. (p < 0.05, FDR < 0.05). Finally, the fraction of tumors showing significant enrichment for a particular gene signature in each class (Kras tumors, Kras/Lkb1 primary tumors and metastasis) was calculated and assigned a p value according to the hypergeometric distribution (p < 0.01, FDR < 0.05). Gene Set Enrichment analysis of short-term treated Kras/Lkb1 tumors was performed using GSEA (http://broad.mit.edu/gsea) across the complete list of genes ranked by signal-to-noise ratio.
UNC human lung cancer microarrays (Agilent custom 44,000 probe) annotated with KRAS and LKB1 genetic status were mapped to mouse genes using NCBI Homologene, retaining only one-to-one orthologs. Microarray data were sample and gene standardized, and Lkb1 and Mets signature scores were calculated as the median of the genes across the gene set. Statistical significance was calculated using the Wilcoxon rank sum test.
Survival Analysis
The Director's Challenge Consortium human primary lung adenocarcinoma data set was downloaded from http://caarraydb.nci.nih.gov (experiment ID 1015945236141280:1) (Shedden et al., 2008) . MSKK data set 2 was downloaded from http://cbio.mskcc.org/Public/lung_array_data (Nguyen et al., 2009) . Data sets were first log2 transformed, mean-centered data set and loaded into Genomica software. Enrichment of genes that belong to our murine-derived Mets signature was calculated as described above and each patient was assigned an enrichment score. Positive and negative enrichment scores for each individual were matched with survival data (time to last contact or death) or recurrence of metastasis (metastasis-free survival). Kaplan-Meier plots were created with Graphpad software. Statistical significance was calculated using the log-rank test.
Phosphopeptide Immunoprecipitation, Liquid-Chromatography Tandem MS, and Phosphopeptide Analysis We performed phosphotyrosine peptide identification and quantification as described previously (Rikova et al., 2007) . See Supplemental Experimental Procedures for sample preparation and handling. For differential phosphorylation analysis, duplicated intensities were averaged, and fold-changes between different experimental conditions were calculated. For KEGG classification of the phosphoproteins, we used FatiGO software (www.babelomics.org) (Al-Shahrour et al., 2004) . A modification of GSEA (Subramanian et al., 2005) with phosphoprotein sets instead gene sets ( Figure S2A ) was used to interrogate the PhosphoPoint database of tyrosine kinase substrates (http://kinase. bioinformatics.tw) .
Quantitative RT-PCR A total of 50 ng RNA total RNA was reverse transcribed with the Superscript cDNA Synthesis Kit (Invitrogen). RT-PCR reactions were prepared in triplicate for each sample using primers and TaqMan probes purchased from Applied Biosystems (see also Supplemental Experimental Procedures). Reactions were run on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). GAPDH was used as a reference for all reactions. Relative levels of a gene were determined by DDCt method.
Multiplex Bead Analysis
Quantification of TGF-b isoforms and Src family kinase activities were assayed using Human TGF-b 1,2,3 Assay and SRC Family Kinase 8-Plex (Millipore), respectively. Assays were performed according to the manufacturer's specifications and analyzed with a Luminex 100 platform. Fluorescence intensity from duplicate samples was averaged and transformed into protein concentration using a calibration curve obtained with TGFb1, 2, and 3 standards. For Src assay, activity was expressed in mean fluorescence intensity with background correction from duplicate samples. Statistical significance was calculated using a two-sided Student's exact t test.
Western Blot and Kinase Array Analysis
Parameters for western blot and antibodies are available in Supplemental Experimental Procedures. Human phosphokinase arrays (R&D Systems) were performed according to the manufacturer's instructions. The percent control activation/deactivation was determined by densitometric analysis using ImageJ Software (NIH).
Short Hairpin RNA Constructs, Lentiviral Infection, and Small Interfering RNA Infection Short hairpin RNA (shRNA) constructs cloned in pLKO.1 puro vector were designed by the RNAi consortium and distributed by Open Biosystems. shRNA sequences are provided with supplemental experimental procedures. Stable polyclonal cell lines are established as described previously (Shimamura et al., 2008) .
Cell Migration, Invasion, and Adhesion Assays Cell migration in cultures was measured using a two-dimensional in vitro scratch motility assay. A 1 mm wide scratch was made on confluent monolayer in tissue culture slides and allowed to grow under standard conditions for 12 hr. Repopulation of the cleared field was recorded using a Nikon inverted TE2000 and migrated distance was quantified using Image J software. Invasion and adhesion assays kits were obtained from Cell Biolabs and assays were performed according to the manufacturer's specifications. Details are available in the Supplemental Experimental Procedures.
Immunofluorescence Analysis Cells were fixed on four-well chamber glass slides in methanol/acetone (1:1) at -20 C for 10 min and air dried. Primary block was done with 10% goat serum (Sigma) and 0.05% Tween 20 in phosphate-buffered saline for 1 hr at room temperature. A mouse monoclonal antibody for activated b-catenin (Millipore) was diluted 1:50 in blocking buffer and incubated overnight at 4 C. Rabbit antimouse secondary antibody conjugated with Alexa488 dye (Invitrogen) was diluted 1:100 in blocking buffer and incubated for 1 hr at room temperature. Images were acquired using a Nikon inverted TE2000 microscope equipped a Hamamatsu Orca ER digital CCD camera.
In Vivo Xenograft Experiments
The 5-to 6-week-old female nu/nu mice (Charles River) were maintained under pathogen-free conditions. Tumors were generated by injecting subcutaneous 5 3 10 6 cells mixed with reconstituted basement membrane Matrigel (BD Biosciences) with 1:1 ratio in PBS. Animals were sacrificed 14 days after inoculation, and tumors were excised and fixed in formalin. Tumor measurements were obtained using electronic calipers. Tumor volume was calculated using: Tumor volume = (length 3 width 2 )/2. We compared tumor volumes of mice using a two-sided Student's exact t test.
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Cancer Therapy with Inhibitors Dual PI3K-mTOR inhibitor, NVP-BEZ235-AN (Novartis Institutes for Biomedical Research) was reconstituted in one volume of N-methyl-2-pyrrolidone (69118, Fluka) and nine volumes of PEG300 (81160, Fluka) and administered by oral gavage. MEK inhibitor ARRY-142886 (AZD6244, Otava Chemicals) and Dasatinib (LC Labs) were reconstituted in 0.5% methyl cellulose (Fluka) and 0.4% polysorbate (Tween 80; Fluka) and administered by oral gavage. Dosages are indicated in the figure legends.
MRI and Tumor Volume Measurement
We performed MRI measurements as described previously (Engelman et al., 2008) . Brief descriptions are available in the Supplemental Experimental Procedures.
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